<DOC>
	<DOCNO>NCT03047395</DOCNO>
	<brief_summary>The purpose study investigate long-term safety efficacy risankizumab treatment moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Risankizumab Maintenance Moderate Severe Plaque Type Psoriasis</brief_title>
	<detailed_description>This Phase 3 , single-arm , multicenter OLE study design investigate long-term safety efficacy 150 mg risankizumab treatment moderate severe chronic plaque psoriasis . Approximately 1900 subject meet entry criterion plan enrol study , roll precede Phase 2/3 study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects history moderate severe chronic plaque psoriasis , complete one preceding study . Subjects must candidate prolong open label risankizumab treatment accord investigator judgment . Premature discontinuation reason precede study . Subjects develop guttate , erythrodermic , pustular druginduced psoriasis diagnose investigator precede study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
</DOC>